Morteza Izadi

Morteza Izadi

Auto-generated profile, based on publicly available information

Morteza Izadi

Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
RKReza Karbalaee
Reza Karbalaee
SMSaber Mehdizadeh
Saber Mehdizadeh
HGHadi Esmaeili Gouvarchin Ghaleh
Hadi Esmaeili Gouvarchin Ghaleh
MIMorteza Izadi
Morteza Izadi
BKBahman Jalali Kondori
Bahman Jalali Kondori
SHSeyed Morteza Hosseini
Seyed Morteza Hosseini
Background: Cancer is a major cause of death worldwide. Colorectal cancer is the second most common type. Additional treatments like chemotherapy and radiation therapy may be recommended. Developing new techniques is vital due to drug resistance and a lack of targeted therapies. Objective: In this study, the effects of mesenchymal stem cells (MSCs) loaded with oncolytic Coxsackievirus A21 (CVA21) on a mouse model of CRC were investigated. Methods: The therapeutic potency of MSCs loaded with oncolytic CVA21 were evaluated in an experimental mouse model of colorectal cancer which received an injection CT26 cells per mouse subcutaneously. Splenocyte proliferation index, lactate dehydrogenase (LDH) assay, nitric oxide (NO) production assessment, and cytokine assay (IFN-γ, IL-4, IL-10, and TGF-β) in the splenocyte supernatant were all used to evaluate the impact of MSCs loaded with CVA21. Results: The results of this study showed that the treatment of a mouse model of colorectal cancer with MSCs loaded with oncolytic CVA21 could significantly suppress the tumor growth, which was accompanied by stimulation of splenocytes proliferation index, an increase of NO and LDH. Also, MSCs loaded with oncolytic CVA21 increased the secretion of IFN-γ and decreased the secretion of IL-4, IL-10, and TGF-β. Conclusion: The results of the current study suggest that MSCs loaded with oncolytic CVA21 therapy for the CRC mouse model may have some potential advantages. On the other hand, the results of the study showed that, in addition to activating the acquired immune system, the use of MSCs loaded with oncolytic CVA21 also stimulates the innate immune system by increasing level of nitric oxide.

3 January 2025 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
ARAlireza Tavasoli Rostami
Alireza Tavasoli Rostami
MIMorteza Izadi
Morteza Izadi
MEMohsen Saberi Esfeedvajani
Mohsen Saberi Esfeedvajani
MRMehdi Raei
Mehdi Raei
MSMostafa Soodmand
Mostafa Soodmand
MBMahdi Bagheri
Mahdi Bagheri

31 March 2026 in Russian Open Medical Journal
Verified
Journal Article
Closed access
RDReza Dadfar
Reza Dadfar
MGMaryam Ghorbani
Maryam Ghorbani
MIMorteza Izadi
Morteza Izadi
HGHADI ESMAEILI GOUVARCHIN GHALEH
HADI ESMAEILI GOUVARCHIN GHALEH
MSMojtaba Sepandi
Mojtaba Sepandi
JSJavad Sarshoori
Javad Sarshoori
Background — Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by polycystic ovaries and associated oxidative stress. This study assessed the potential beneficial effects of ozone therapy on ovarian tissue in mice with induced PCOS. Methods — Forty-two female mice were distributed between six groups: a control group, a PCOS group, a PCOS group treated with ozone (45, 60, and 70 μg/mL), and a PCOS group treated with clomiphene citrate (1.5 mg/kg). PCOS was induced by injection of estradiol valerate (EV), and treatment was administered for four weeks. Data were analyzed using SPSS software, with a significance level of p

26 June 2022 in Journal of Antioxidant Activity
Verified
Journal Article
Open access
FSFarshad Shahi
Farshad Shahi
SRShabnam Rahimi
Shabnam Rahimi
VMVahan Moradians
Vahan Moradians
NJNematollah Jonaidi Jafari
Nematollah Jonaidi Jafari
MIMorteza Izadi
Morteza Izadi

15 December 2021 in Hospital Practices and Research
Verified
Journal Article
Open access
PDF file
SSSoraya Shadmanfar
Soraya Shadmanfar
GAGholamhosein Alishiri
Gholamhosein Alishiri
NBNoushin Bayat
Noushin Bayat
MIMorteza Izadi
Morteza Izadi
ASAhmad Salimzadeh
Ahmad Salimzadeh
ASAmin Saburi
Amin Saburi
Background: Among suggested medications for the treatment of COVID-19, chloroquine derivates and angiotensin-converting– enzyme inhibitors (ACEIs)/angiotensin II type 1 receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease. Objectives: The present study aimed to evaluate COVID-19 in patients with rheumatic diseases receiving chloroquine derivate. Methods: Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June 2020. At first, the symptoms of COVID-19 were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-19 infection status and another time according to their hydroxychloroquine use. Results: 1159 patients enrolled in the study with a mean age of 49.39 years. Frequency of hypertension was 22.17 %, diabetics (9.49%) and 20 (1.7%) patients were positive for COVID-19 testing. The most common symptoms of the COVID-19 positive cases were cough (5.2%) and fever (4%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-19 positive or negative patients. Among the patients receiving hydroxychloroquine, 15 patients (1.7%) had proved COVID-19 versus 5 patients (1.7%) who were not receiving these medications (P>0.999). Conclusion: The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-19. Moreover, receiving chloroquine derivate was not related to the development of COVID-19 in patients with rheumatologic disorders.